Should aspirin be replaced with ADP blockers and anti-GPVI to manage thrombosis?
Platelets have a pivotal role in maintaining cardiovascular homeostasis. They are kept docile by endothelial-derived mediators. Aberration in haemostatic balance predisposes an individual to an elevated risk of a prothrombotic environment. Anti-platelet therapy has been a key component to reduce thi...
Main Authors: | Hafsa Khan, Tahira Ghulam, Naseer Ahmed, Muhammad Rafai Babar, Simon DJ Calaminus, Muhammad Zuhair Yusuf |
---|---|
Format: | Article |
Language: | English |
Published: |
Bioscientifica
2023-01-01
|
Series: | Vascular Biology |
Subjects: | |
Online Access: | https://vb.bioscientifica.com/view/journals/vb/5/1/VB-22-0010.xml |
Similar Items
-
Antithrombotic Therapy in Patients with Coronary Artery Disease and Prior Stroke
by: Elisa Bellettini, et al.
Published: (2021-04-01) -
Comparison of ESC and ACCF/AHA Guidelines for Oral Antiplatelet Treatment in the Management of Patients with Acute Coronary Syndrome
by: Ayhan Sarıtaş, et al.
Published: (2016-09-01) -
Efficacy and safety of antiplatelet drugs in patients with chronic kidney disease
by: İbrahim Yıldız, et al.
Published: (2014-07-01) -
Trends in Spending and Claims for P2Y12 Inhibitors by Medicare and Medicaid From 2015 to 2020
by: Mohammed Essa, et al.
Published: (2023-04-01) -
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study
by: Francesco Franchi, et al.
Published: (2020-04-01)